Ilsung Pharm Market Cap ($102.65 Million)
Market Cap & Net Worth: Ilsung Pharm (003120)
Ilsung Pharm market cap. Ilsung Pharm (KO:003120) has a market capitalization of $102.65 Million (₩151.48 Billion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18908 globally and #897 in its home market, demonstrating a -2.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilsung Pharm's stock price ₩21150.00 by its total outstanding shares 7162047 (7.16 Million). Also see Ilsung Pharm (003120) cash conversion ratio for how efficiently the company converts equity into cash flow.
Ilsung Pharm Market Cap History (2015–2026)
Ilsung Pharm market cap history from 2015 to 2026. Data shows growth from $76.65 Million to $102.65 Million (3.60% CAGR). Check Ilsung Pharm (003120) stock price for real-time trading data and today's change.
Ilsung Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilsung Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Ilsung Pharm to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Ilsung Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.09x
Ilsung Pharm's market cap is 0.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $82.86 Million | $67.46 Billion | $3.02 Billion | 0.00x | 0.03x |
| 2017 | $90.77 Million | $67.04 Billion | $2.63 Billion | 0.00x | 0.03x |
| 2018 | $65.27 Million | $61.65 Billion | $2.95 Billion | 0.00x | 0.02x |
| 2019 | $56.57 Million | $48.41 Billion | $6.72 Billion | 0.00x | 0.01x |
| 2020 | $57.51 Million | $40.60 Billion | $3.22 Billion | 0.00x | 0.02x |
| 2021 | $51.84 Million | $42.09 Billion | -$1.37 Billion | 0.00x | N/A |
| 2022 | $77.42 Million | $61.25 Billion | $105.24 Billion | 0.00x | 0.00x |
| 2023 | $114.79 Million | $78.05 Billion | -$20.94 Billion | 0.00x | N/A |
| 2024 | $75.23 Million | $69.02 Billion | $13.09 Billion | 0.00x | 0.01x |
| 2025 | $105.81 Million | $64.29 Billion | $1.17 Billion | 0.00x | 0.09x |
Competitor Companies of 003120 by Market Capitalization
Companies near Ilsung Pharm in the global market cap rankings as of November 3, 2026. Also see Ilsung Pharm balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Ilsung Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Ilsung Pharm (2015–2026)
Market capitalization of Ilsung Pharm from 2015 to today. Between 2015 and today, Ilsung Pharm's market cap moved from $76.65 Million to $ 102.65 Million, with a yearly change of 3.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩102.65 Million | -2.98% |
| 2025 | ₩105.81 Million | +40.65% |
| 2024 | ₩75.23 Million | -34.46% |
| 2023 | ₩114.79 Million | +48.27% |
| 2022 | ₩77.42 Million | +49.34% |
| 2021 | ₩51.84 Million | -9.85% |
| 2020 | ₩57.51 Million | +1.66% |
| 2019 | ₩56.57 Million | -13.33% |
| 2018 | ₩65.27 Million | -28.10% |
| 2017 | ₩90.77 Million | +9.55% |
| 2016 | ₩82.86 Million | +8.09% |
| 2015 | ₩76.65 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Ilsung Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $102.65 Million USD |
| MoneyControl | $102.65 Million USD |
| MarketWatch | $102.65 Million USD |
| marketcap.company | $102.65 Million USD |
| Reuters | $102.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more